German biotechnology company BioNTech SE (Nasdaq:BNTX), the development partner with Pfizer for a COVID-19 vaccine, on 24 September 2020 joined other leading COVID-19 vaccine developers in ruling out participation in Britain's plans to test experimental inoculations by deliberately infecting trial volunteers.
According to a spokesman of the company, "BioNTech's vaccine candidate is not part of this study."
Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.
AstraZeneca and Sanofi both have said their vaccine candidates were not involved in the programme, Reuters added.
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Piramal Pharma acquires controlling stake in Yapan Bio
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB